PRAX News and Press, Praxis Precision Medicines Inc. From 03/21/22

BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibiti...

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibiti...

Praxis Precision Medicines, Inc. (PRAX) Q4 2021 Earnings Conference Call February 28, 2022, 8:30 AM ET Company Participants Marcio Souza – President and Chief Executive Officer Bernard Ravina – Chief Medical Officer Alex Kane – Vice President of Investor Relations and Cor...

The following slide deck was published by Praxis Precision Medicines, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Praxis Precision Medicines, Inc. 2022 Q4 - Results - Earnings Call Presentation

Praxis Precision Medicines press release (NASDAQ:PRAX): Q4 GAAP EPS of -$1.30. As of December 31, 2021, Praxis had $275.9 million in cash, cash equivalents and marketable securities, compared to $296.6 million in cash and cash equivalents as of December 31, 2020 For further details see: ...

PRAX-114 Phase 2/3 monotherapy MDD Aria Study topline results expected in June 2022 PRAX-944 Phase 2a ET topline results expected in May 2022; to include open-label and placebo-controlled withdrawal data PRAX-222 seamless study in SCN2A-DEE expected to initiate in 2Q22 ...

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibitio...

PRAX-562 demonstrated robust preclinical antiseizure activity and exhibited an improved preclinical tolerability profile compared to standard-of-care Praxis expects to initiate a Phase 2 trial in the first half of 2022 to explore the potential for PRAX-562 to treat rare DEEs ...

BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today ann...

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today ann...